Omid Yazdanpanah

Dr. Omid Yazdanpanah

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
PJParnian Jabbari
Parnian Jabbari
OYOmid Yazdanpanah
Omid Yazdanpanah
DBDavid Benjamin
David Benjamin
AKArash Rezazadeh Kalebasty
Arash Rezazadeh Kalebasty
There is a rising trend in the consumption of dietary supplements, especially among adults, with the purpose of improving health. While marketing campaigns tout the potential health benefits of using dietary supplements, it is critical to evaluate the potential harmful effects associated with these supplements as well. The majority of the scarce research on the potential harmful effects of vitamins focuses on the acute or chronic toxicities associated with the use of dietary supplements. Quality research is still required to further investigate the risks of long-term use of dietary supplements, especially the risk of developing cancers. The present review concentrates on studies that have investigated the association between the risk of developing cancers and associated mortality with the risk of dietary supplements. Such an association has been reported for several vitamins, minerals, and other dietary supplements. Even though several of these studies come with their own shortcomings and critics, they must draw attention to further investigate long-term adverse effects of dietary supplements and advise consumers and healthcare providers to ponder the extensive use of dietary supplements.

8 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OYOmid Yazdanpanah
Omid Yazdanpanah
DBDavid Benjamin
David Benjamin
AKArash Rezazadeh Kalebasty
Arash Rezazadeh Kalebasty
Prostate cancer has the highest incidence among all cancers in men. Sexual minorities, including gay and bisexual men, as well as transgender, were previously a “hidden population” that experienced prostate cancer. Although there continues to remain a paucity of data in this population, analyses from studies do not reveal whether this population is more likely to endure prostate cancer. Nonetheless, several qualitative and quantitative studies have established worse quality-of-life outcomes for sexual minorities following prostate cancer treatment. Increased awareness of this previously “hidden population” among healthcare workers, as well as more research, is warranted to gain further understanding on potential disparities faced by this growing population.

20 December 2024 in Current Problems in Cancer
Verified
Journal Article
Open access
AMAditya Mahadevan
Aditya Mahadevan
OYOmid Yazdanpanah
Omid Yazdanpanah
VPVivek Patel
Vivek Patel
DBDavid Benjamin
David Benjamin
AKArash Rezazadeh Kalebasty
Arash Rezazadeh Kalebasty
Genitourinary cancers affect over 480,000 patients in the United States annually. While promising therapeutic modalities continue to emerge, notably immune checkpoint inhibitors, molecular targeted therapies, antibody-drug conjugates, and radioligand therapies, these treatments are associated with a spectrum of adverse side-effects, including ophthalmologic toxicities. In this review, we cover the most commonly used antineoplastic agents for the kidneys, bladder, urinary tracts, prostate, testis, and penis, detailing mechanism, indication, and recent trials supporting their use. For each category of antineoplastic therapy, we describe the epidemiology, management, and clinical presentation, of common ophthalmologic toxicities stemming from these agents. This review serves to augment awareness and recognition of possible ophthalmologic manifestations resulting from the use of antineoplastic agents in genitourinary malignancy. Early identification of these side effects can hasten ophthalmology referral and ultimately improve visual outcomes in patients experiencing medication-induced ocular toxicities.

24 August 2020 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
OYOmid Yazdanpanah
Omid Yazdanpanah
JKJasleen Kaur
Jasleen Kaur
ISIrfan Shafi
Irfan Shafi
HSHousam A Sarakbi
Housam A Sarakbi
We present the case of a 45-year-old man with a known history of sarcoidosis who presented with double vision and headache. On examination, he was found to have left abducens and hypoglossal nerve palsy. CT and then MRI demonstrated extensive osseous lesions with a large expansile mass involving the clivus bone and sphenoid sinus. Laboratory data were remarkable for normocytic anaemia, low anion gap and elevated total protein which raised the suspicion for multiple myeloma. Subsequent protein electrophoresis and immunofixation illustrated monoclonal spike of IgG lambda present in the gamma zone. This was followed by a bone marrow biopsy that demonstrated plasma cells compromising around 80% of marrow cellularity. Left sphenoidal mass biopsy was consistent with plasmacytoma. Based on these findings, the patient was initially started on palliative radiation to shrink the intracranial tumour and is currently undergoing induction chemotherapy.

1 February 2025 in Integrative Cancer Therapies
Verified
Journal Article
Open access
PJParnian Jabbari
Parnian Jabbari
OYOmid Yazdanpanah
Omid Yazdanpanah
DBDavid J. Benjamin
David J. Benjamin
AKArash Rezazadeh Kalebasty
Arash Rezazadeh Kalebasty
Ayurveda is commonly utilized in the treatment of medical ailments but has yet to gain traction in incorporation into allopathic medicine. Prostate cancer is the most common cancer among men and presents a significant public health burden across the globe. Despite advancements in the management of advanced prostate cancer including androgen deprivation therapy and novel hormonal therapies, men may eventually develop resistance to hormonal therapy. As such, there is an urgent need for novel therapeutic options in treating this malignancy. This review examines the pre-clinical evidence for Ayurveda medicinal plants such as Withania somnifera , Glycyrrhiza spp, Momordica spp, Boswellia , and Bacopa monnieri and their potential application in managing prostate cancer. Several in-vitro and pre-clinical studies suggest potentials for these plants or their derivatives in preventing or treating prostate cancers. Despite strong evidence of efficacy of these plants to potentially improve the outcome of prostate cancer, clinical trials are required to evaluate which plants may be most efficacious and to determine effective dosing strategies, as well as the use of ayurvedic plants as standalone therapies or in combination with conventional prostate cancer treatments.

3 January 2024 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
OYOmid Yazdanpanah
Omid Yazdanpanah
FLFa-Chyi Lee
Fa-Chyi Lee
RHRoozbeh Houshyar
Roozbeh Houshyar
MNMahra Nourbakhsh
Mahra Nourbakhsh
NMNataliya Mar
Nataliya Mar
Gastroesophageal junction hepatoid adenocarcinoma is a rare form of gastroesophageal cancer. We present a case of a 38-year-old man with no significant medical history who was diagnosed with gastroesophageal junction hepatoid adenocarcinoma but initially misdiagnosed with a testicular germ cell tumor, given the elevated alpha-feto protein and poorly differentiated pathology. We will elaborate on the importance of gene expression profiling in modern oncology to better define the tumor of origin in patients with cancer of unknown primary origin, how it helped us to diagnose gastroesophageal junction hepatoid adenocarcinoma and how it can help identify potential additional therapeutic targets in some cases. Due to the rarity of this subtype of gastroesophageal junction cancer there is a lack of standard therapeutic options, and we will discuss the most commonly used treatment regimens. The patient underwent three lines of antineoplastic therapy and unfortunately passed after 51 weeks of follow-up.